News Grifols board backs IPO for US business Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.
News Grifols slides as Brookfield pulls out of takeover talks Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's shares
Patients Challenges and opportunities with plasma-derived therapies This newest pharmaphorum podcast welcomes Takeda's Dr Kristina Allikmets.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
